The Liverpool BRAIN (Brain Research Advanced Imaging Network)

Research

Quantitative neuroimaging approaches are ­in-vivo and non-invasive methods to measure brain function and architecture on the macroscopic and mesoscopic scale. The increasing sophistication of MRI systems and image analysis techniques allow us to interrogate the human brain in a safe way on an increasingly detailed level.

Some of our current work and applications include:

Epilepsy

  • The identification of preoperative imaging biomarkers of postoperative seizure outcome in patients with refractory focal epilepsy.
  • The development and application of network imaging approaches to identify novel prognostic markers of anti-epileptic drug treatment outcome in newly diagnosed epilepsy.
  • The use of quantitative neuroimaging to understand cognitive dysfunction in focal epilepsy.
  • The prediction of epilepsy from a first seizure using MRI, electrophysiological and biological approaches.
  • The development of MRI analysis tools for the automated detection of epileptogenic lesions causing seizures.
  • The application of novel MRI techniques to differentiate intra-axonal degeneration from inter-axonal inflammatory changes in epilepsy.
  • Understanding brain structural and functional connectivity alterations in genetic generalised epilepsy.
  • The investigation of associated genomic risk factors and quantitative neuroimaging measures in epilepsy.
  • The identification of brain architectural alterations in canine patients with idiopathic epilepsy.

Brain infections

  • To determine the relationship between neuropsychological impairment and brain damage in encephalitis.
  • The development of quantitative neuroimaging markers of drug treatment outcome in herpes simplex encephalitis and autoimmune encephalitis.
  • Quantitative neuroimaging in Neurocysticercosis and the identification of clinical and imaging factors associated with the presentation of intractable seizures.

Neurodegeneration

  • The identification of architectural pathways affected in the early stages of Parkinson’s disease.
  • Understanding central and peripheral neurodegeneration in prediabetes and early Type 2 diabetes.